ESMO 2023 | Darovasertib and crizotinib in uveal melanoma

Meredith McKean, MD, MPH, Sarah Cannon Research Institute, London, UK, comments on findings from a Phase I/II trial (NCT03947385) of darovasertib, an oral protein kinase C (PKC) inhibitor, and crizotinib in patients with uveal melanoma. Patients receiving darovasertib and crizotinib had promising response rates, and levels of circulating tumor DNA (ctDNA) were reduced in a majority of patients. A manageable safety profile was additionally observed. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.